Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | CTRC | Q99895 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27467028 | 0.79 | ALDH1A1 (0.48) | ELANECASP1MAPTKDM4EALDH1A1 | |
| SCHEMBL7863330 | 0.79 | ELANE (0.70) | ELANECASP1 | |
| SCHEMBL7205622 | 0.76 | ELANE (0.59) | ELANECASP1 | |
| SCHEMBL8200206 | 0.76 | ELANE (0.39) | ELANECASP1 | |
| SCHEMBL27448341 | 0.74 | ALDH1A1 (0.44) | ELANECASP1MAPTKDM4EALDH1A1 | |
| SCHEMBL27395657 | 0.72 | CMA1 (0.70) | CMA1CTRC | |
| SCHEMBL27417159 | 0.69 | DHODH (0.43) | ELANECASP1MAPTKDM4EALDH1A1 | |
| SCHEMBL7208083 | 0.68 | ELANE (0.68) | ELANECASP1 | |
| SCHEMBL27467970 | 0.67 | KDM4E (0.44) | CASP1MAPTKDM4EALDH1A1GLA | |
| SCHEMBL6556086 | 0.66 | ELANE (0.80) | ELANECMA1CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010003750-A1 | N-(pyrimidinyl)-aspartic acid analogs as interleukin-1beta converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2001-06-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003750-A1 | N-(pyrimidinyl)-aspartic acid analogs as interleukin-1beta converting enzyme inhibitors | IL1A, IL1B, IL1RN | ELANE 74/4885CASP1 11/4885MAPT 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.